Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by CLEMENS, G. R.
Right arrow Articles by THYSSEN, J. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CLEMENS, G. R.
Right arrow Articles by THYSSEN, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 Oxford University Press

other

Teratological, Neurochemical, and Postnatal Neurobehavioral Assessment of METASYSTOX-R, an Organophosphate Pesticide in the Rat

G. R. CLEMENS*,1, R. E. HARTNAGEL*, J. J. BARE* and J. H. THYSSEN{dagger}

*Toxicology Department, Miles Laboratories, Incorporated P.O. Box 40, Elkhart, Indiana 46515 {dagger}Toxicology Department, Mobay Corporation, Stanley Research Center 17745 South Metcalf, Stilweli, Kansas 66085

Received March 2, 1989; accepted August 1, 1989

Teratological, Neurochemical, and Postnatal Neurobehavioral Assessment of METASYSTOX-R, an Organophosphate Pesticide in the Rat. CLEMENS, G. R., HARTNAGEL, R. E., BARE, J. J., AND THYSSEN, J. H. (1990). Fundam. Appl. Toxicol. 14, 131–143. The purpose of this study was to assess the embryotoxic, fetotoxic, and teratogenic potential of METASYSTOX-R (MSR) in the rat. Furthermore, the study was designed to determine if maternally toxic doses of MSR altered fetal brain acetylcholinesterase (AChE), compromised neonatal survival, growth, and development, or affected neurobehavioral development. Inseminated female rats (45/dose group) received single daily oral doses of 0, 0.5, 1.5, or 4.5 mg/kgofMSR from Days 6 to 15. Dose groups were subdivided into three termination phases: Phase 1,5 females terminated on Day 16 of gestation; Phase II, 28 females terminated on Day 20 of gestation; Phase III, 12 females terminated on Day 21 postpartum. MSR produced a dose-related reduction in maternal plasma (30–72%), red blood cell (18-56%), and brain (21-68%) cholinesterase (ChE) activity, when measured on Day 16 of gestation. The high dose of MSR significantly (p ≤ 0.05) reduced food consumption, suppressed body weight gain, and produced tremors in 98% of the dams. MSR administered at maternally toxic doses as high as 4.5 mg/kg was devoid of embryotoxic, fetotoxic, and teratogenic effects. Fetal brain AChE was not substantially different from control for any dose level in Day 20 fetuses. Furthermore, neonatal survival, growth, and development were unaffected and an extensive neurobehavioral testing scheme demonstrated no alteration of sensory or reflex functions, maze learning ability, or open field activity for neonates.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.